ENGN
enGene Holdings Inc. · Healthcare
7.33
1.24%(+0.09)
Close7.98
8.87%(+0.65)
After HoursLast Updated: — ET
52W L: $2.6552W H: $12.25
$7.33
CHG-0.64 (-8.03%)
H$8.39
L$6.01
VOL11M
ENGN (1h)
ENGN NEWS
businesswire.com
14h ago
enGene Announces Name Change to enGene Therapeutics Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to “enGene Therapeutics Inc.” effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's on.
defenseworld.net
Mar 26
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Moderate Buy” from Analysts
enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has issued a
defenseworld.net
Mar 17
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Executives from enGene (NASDAQ: ENGN) provided an update on the company's detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions, and commercial planning as the study advances. Protocol amendments and response-rate improvement In discussing modifications to the NMIBC trial protocol, the company highlighted three changes: T1 re-resection, TA reinduction, and a
defenseworld.net
Mar 17
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
enGene (NASDAQ: ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company's approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company's view that its investigational therapy, detalimogene, could be designed to fit more easily into community urology practices.
seekingalpha.com
Mar 12
enGene Holdings: Key Catalysts Incoming For 2026
enGene Holdings remains on track with a cautiously optimistic 'Buy' rating, supported by promising clinical data and strong financial positioning. ENGN's lead candidate, detalimogene voraplasmid, demonstrated a 63% complete response rate at 3 months in NMIBC, with favorable tolerability and pivotal cohort enrollment exceeding targets. ENGN plans a pivotal LEGEND cohort update at a spring 2026 medical conference, with a BLA submission for FDA approval anticipated in the second half of 2026.
seekingalpha.com
Mar 10
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript